Wird geladen...
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin Expressing Cancers
PURPOSE: MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen over-expressed in pancreatic cancer, ovarian cancer, mesothelioma and other malignancies. We conducted a Phase I clinical trial of MORAb-009 in patients with advanced mesothelin expressing c...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2010
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3057907/ https://ncbi.nlm.nih.gov/pubmed/21037025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2275 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|